Table 1.
Study | Characteristics of the Study | Findings |
---|---|---|
LEADER 2018 [55] |
RCT liraglutide (n = 4364) vs. placebo (n = 4321) Follow-up: 3.5–5 years |
|
Mali et al. 2020 [58] |
Case/non-case analysis on report EudraVigilance 11,243 cases of thyroid cancer (236 involved GLP-1 RAs) until 30 January 2020 |
|
Bezin et al. 2023 [56] |
Nested case–control analysis subjects with thyroid cancer (n = 2562) vs. controls (n = 45,184) |
|
Silverii et al. 2023 [62] |
Meta-analysis of 64 RCT GLP-1 RAs (n = 46,228) vs. any comparator (n = 38,399) |
|
Bea et al. 2023 [60] |
Population-based cohort study New users of GLP-1 RAs (n = 21,722) vs. new users of SGLT2i (n = 326,993) |
|
Feier et al. 2024 [61] |
Systematic review of 10 RCT (use of semaglutide) n = 14,550 with 7830 receiving semaglutide |
|